Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies

Meeting the need for innovation in both upstream and downstream AAV viral vector bioprocess technology is a crucial step towards ensuring the continued emergence of the commercial gene therapy sector. A second and closely related one is evolving the analytics required to ensure consistent, robust and cost-effective manufacture. In this webinar, Thermo Fisher Scientific will describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.

Learning Objectives


Speaker Information

Brandon Pence

Brandon Pence
Vice President and General Manager, Purification and Pharma Analytics
Thermo Fisher Scientific

Brandon Pence serves as VP and General Manager of the Purification and Pharma Analytics business in Salt Lake City, Utah. Brandon Pence has more than 20 years of experience in the life sciences industry leading teams in R&D, product management, marketing and business strategy.

Richard Snyder

Richard Snyder, PhD
Vice President, Science & Technology, Pharma Services, Viral Vector Services
Thermo Fisher Scientific

Dr. Richard O. Snyder, Ph.D. is the VP for Science and Technology, Pharma Services, Viral Vector Services at Thermo Fisher Scientific. Dr. Snyder has been investigating virus biology, vector development, cGMP vector manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 33 years and was a member of the teams who developed novel viral vector-based human gene therapies.

Kate Torchilin

Kate Torchilin
Vice President and General Manager, Cell Culture and Cell Therapy
Thermo Fisher Scientific

Dr. Kate Torchilin, Ph.D. is VP and General Manager of Cell Culture & Cell Therapy, BioProduction at Thermo Fisher Scientific. Kate previously was responsible for Purification & Pharma Analytics, BioProduction at Thermo Fisher Scientific.

(*Indicates a mandatory field)


For research use or further manufacturing, not for diagnostic use or direct administration in humans or animals.